search button
Open Access

Expression of miR‑204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells

  • Authors:
    • Jian Ding
    • Xiaoyun Lu

  • View Affiliations

  • Published online on: September 27, 2018     https://doi.org/10.3892/ol.2018.9519
  • Pages: 7152-7157

  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Expression, clinical significance and molecular mechanism of miR‑204 in human retinoblastoma (RB) and para‑carcinoma tissues were investigated. A total of 110 cases of RB tissues preserved after ophthalmectomy in the First Affiliated Hospital of Hunan Normal University (People's Hospital of Hunan Province) from April 2013 to June 2017 were collected along with 100 cases of para‑carcinoma normal tissues. The expression of miR‑204 in RB tissues was detected via reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), and its associations with clinicopathological features were analyzed. Y79 cells were transfected with miR‑204 mimics. A total of 80 pmol/l miR‑204 mimics and 10 µl Lipofectamine 2000 were added into the experimental group. Cell proliferation was detected via methyl thiazolyl tetrazolium (MTT) assay at 24, 48, 72 and 96 h, apoptosis was detected via flow cytometry at 48 h after transfection, and the relative expression levels of B‑cell lymphoma 2 (Bcl‑2) messenger RNA (mRNA) and Sirt1 mRNA were detected via RT‑qPCR. The results of MTT assay revealed that the measured value of the optical density (OD) in the experimental group at 48 h was obviously lower than that in the negative control group (p<0.001). The proportion of apoptotic cells in the experimental group was remarkably higher than that in the negative control group (p<0.001). Compared with those in the negative control group, the relative expression levels of Bcl‑2 and Sirt1 mRNAs in the experimental group were significantly decreased (p<0.001). miR‑204 may be involved in the occurrence and development of RB, which is significantly associated with clinical tissue differentiation, neural infiltration and lymph node metastasis in patients. miR‑204 may inhibit proliferation and promote apoptosis of RB cells through downregulating the expression of Bcl‑2 and Sirt1 in RB. Therefore, miR‑204 may become a new biological index for early diagnosis, prognosis evaluation and biotherapy of RB.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ding J and Lu X: Expression of miR‑204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells. Oncol Lett 16: 7152-7157, 2018.
APA
Ding, J., & Lu, X. (2018). Expression of miR‑204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells. Oncology Letters, 16, 7152-7157. https://doi.org/10.3892/ol.2018.9519
MLA
Ding, J., Lu, X."Expression of miR‑204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells". Oncology Letters 16.6 (2018): 7152-7157.
Chicago
Ding, J., Lu, X."Expression of miR‑204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells". Oncology Letters 16, no. 6 (2018): 7152-7157. https://doi.org/10.3892/ol.2018.9519